261 related articles for article (PubMed ID: 29610476)
1. Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice.
Rogers ZN; McFarland CD; Winters IP; Seoane JA; Brady JJ; Yoon S; Curtis C; Petrov DA; Winslow MM
Nat Genet; 2018 Apr; 50(4):483-486. PubMed ID: 29610476
[TBL] [Abstract][Full Text] [Related]
2. Rapid modelling of cooperating genetic events in cancer through somatic genome editing.
Sánchez-Rivera FJ; Papagiannakopoulos T; Romero R; Tammela T; Bauer MR; Bhutkar A; Joshi NS; Subbaraj L; Bronson RT; Xue W; Jacks T
Nature; 2014 Dec; 516(7531):428-31. PubMed ID: 25337879
[TBL] [Abstract][Full Text] [Related]
3. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo.
Rogers ZN; McFarland CD; Winters IP; Naranjo S; Chuang CH; Petrov D; Winslow MM
Nat Methods; 2017 Jul; 14(7):737-742. PubMed ID: 28530655
[TBL] [Abstract][Full Text] [Related]
4. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.
Ng SR; Rideout WM; Akama-Garren EH; Bhutkar A; Mercer KL; Schenkel JM; Bronson RT; Jacks T
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):513-521. PubMed ID: 31871154
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
7. Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma.
Yousefi M; Andrejka L; Szamecz M; Winslow MM; Petrov DA; Boross G
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2303224120. PubMed ID: 37695905
[TBL] [Abstract][Full Text] [Related]
8. A pipeline for rapidly generating genetically engineered mouse models of pancreatic cancer using in vivo CRISPR-Cas9-mediated somatic recombination.
Ideno N; Yamaguchi H; Okumura T; Huang J; Brun MJ; Ho ML; Suh J; Gupta S; Maitra A; Ghosh B
Lab Invest; 2019 Jul; 99(8):1233-1244. PubMed ID: 30728464
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 knockin mice for genome editing and cancer modeling.
Platt RJ; Chen S; Zhou Y; Yim MJ; Swiech L; Kempton HR; Dahlman JE; Parnas O; Eisenhaure TM; Jovanovic M; Graham DB; Jhunjhunwala S; Heidenreich M; Xavier RJ; Langer R; Anderson DG; Hacohen N; Regev A; Feng G; Sharp PA; Zhang F
Cell; 2014 Oct; 159(2):440-55. PubMed ID: 25263330
[TBL] [Abstract][Full Text] [Related]
10. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.
Bolan PO; Zviran A; Brenan L; Schiffman JS; Dusaj N; Goodale A; Piccioni F; Johannessen CM; Landau DA
Cell Syst; 2020 Jan; 10(1):52-65.e7. PubMed ID: 31668800
[TBL] [Abstract][Full Text] [Related]
11. In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor.
Hong H; Yao S; Zhang Y; Ye Y; Li C; Hu L; Sun Y; Huang HY; Ji H
PLoS Genet; 2020 Nov; 16(11):e1009168. PubMed ID: 33137086
[TBL] [Abstract][Full Text] [Related]
12. Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma.
Caswell DR; Chuang CH; Ma RK; Winters IP; Snyder EL; Winslow MM
Mol Cancer Res; 2018 Nov; 16(11):1737-1749. PubMed ID: 30002193
[TBL] [Abstract][Full Text] [Related]
13. Oncogenes and tumor-suppressor genes.
Lehman TA; Reddel R; Peiifer AM; Spillare E; Kaighn ME; Weston A; Gerwin BI; Harris CC
Environ Health Perspect; 1991 Jun; 93():133-44. PubMed ID: 1685442
[TBL] [Abstract][Full Text] [Related]
14. Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9.
Guo T; Chen GQ; Li XF; Wang M; Liu KM; Yang XY; Liu SC; Feng YL; Liu PY; Lin H; Xie AY
Genome Med; 2023 Oct; 15(1):80. PubMed ID: 37803452
[TBL] [Abstract][Full Text] [Related]
15. An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation.
Murray CW; Brady JJ; Tsai MK; Li C; Winters IP; Tang R; Andrejka L; Ma RK; Kunder CA; Chu P; Winslow MM
Cancer Discov; 2019 Nov; 9(11):1590-1605. PubMed ID: 31350327
[TBL] [Abstract][Full Text] [Related]
16. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
17. Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.
Bowden AR; Morales-Juarez DA; Sczaniecka-Clift M; Agudo MM; Lukashchuk N; Thomas JC; Jackson SP
Elife; 2020 May; 9():. PubMed ID: 32441252
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations.
Guernet A; Mungamuri SK; Cartier D; Sachidanandam R; Jayaprakash A; Adriouch S; Vezain M; Charbonnier F; Rohkin G; Coutant S; Yao S; Ainani H; Alexandre D; Tournier I; Boyer O; Aaronson SA; Anouar Y; Grumolato L
Mol Cell; 2016 Aug; 63(3):526-38. PubMed ID: 27453044
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
